News

AbstractBackgroundImmunoglobulin light chain (AL) amyloidosis is a well-recognized complication of multiple myeloma (MM), with important prognostic implications.…

AbstractOur perspective addresses one of the most pressing and timely debates in contemporary neurology and health policy: whether the recent approval of anti-…

In this episode of JACC This Week, Dr. Harlan M. Krumholz and Dr. Carolyn S.P. Lam discuss a dedicated issue of JACC focused on cardiac amyloidosis—one of the…

Cardiac amyloidosis (CA) is present in approximately 10% of patients with heart failure worldwide, with wild-type transthyretin-mediated amyloid cardiomyopathy (…

Despite the proven efficacy of tafamidis in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), real-world treatment decisions often involve…

Minimally invasive skin biopsies may be used to diagnose transthyretin amyloidosis and guide treatment in people with the rare progressive disease, according to the…

ORLANDO, Fla. (Ivanhoe Newswire) --- Cardiac amyloidosis is a systemic disorder that affects the heart and can also affect other organs such as the kidneys and…

Cardiac amyloidosis (CA) is present in approximately 10% of patients with heart failure worldwide, with wild-type transthyretin-mediated amyloid cardiomyopathy (…

Aerska, a startup developing treatments to silence the problematic genes that cause various brain diseases, has raised $39 million in financing, it told STAT…

ransthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. TTR stabilizers bind directly to TTR, inhibiting tetramer dissociation…